USE OF NEUROKININ-1 ANTAGONISTS TO TREAT CHRONIC PRURITUS

摘要

The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, in treating chronic pruritus with a duration of at least about 6 months or 1 year. In some embodiments, the chronic pruritus is characterized by sensitization or hypersensitization of central neuron or/and peripheral neurons. In further embodiments, the chrome pruritus is characterized by spontaneously occurring itch, alloknesis or hyperknesis, or any combination or all thereof. The chronic pruritus can be associated with any medical conditions or can have an unknown cause (idiopathic). One or more additional antipruritic agents can optionally be used in combination with an NK-1 antagonist to treat chronic pruritus.